HENWOOD GERALDINE
Insider CIK 1236451 · TTPH Director · MAPP Director · ALKS Director · REPH President and CEO, Director, 10% owner · BXRX President and CEO, Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| BXRX Baudax Bio, Inc. | P Buy | 2022-12-15 | 2022-12-19 | 1,200 | $2.55 | $3.1K | 2,427 | SEC↗ |
| BXRX Baudax Bio, Inc. | A Award | 2022-06-15 | 2022-06-17 | 39,473 | — | $0 | 49,093 | SEC↗ |
| BXRX Baudax Bio, Inc. | A Award deriv | 2021-12-22 | 2021-12-23 | 821,168 | — | $0 | 821,168 | SEC↗ |
| BXRX Baudax Bio, Inc. | F Tax w/h | 2021-12-15 | 2021-12-23 | 18,636 | $0.31 | $5.8K | 336,716 | SEC↗ |
| BXRX Baudax Bio, Inc. | F Tax w/h | 2021-12-05 | 2021-12-14 | 9,155 | $0.35 | $3.2K | 355,352 | SEC↗ |
| BXRX Baudax Bio, Inc. | P Buy | 2021-09-22 | 2021-09-23 | 8,200 | $0.59 | $4.8K | 364,507 | SEC↗ |
| BXRX Baudax Bio, Inc. | P Buy | 2021-05-07 | 2021-05-10 | 6,000 | $0.83 | $5.0K | 356,307 | SEC↗ |
| REPH Recro Pharma, Inc. | A Award deriv | 2021-04-20 | 2021-04-22 | 38,012 | — | $0 | 38,012 | SEC↗ |
| REPH Recro Pharma, Inc. | A Award deriv | 2021-04-20 | 2021-05-17 | 38,012 | — | $0 | 38,012 | SEC↗ |
| REPH Recro Pharma, Inc. | A Award | 2021-04-20 | 2021-04-22 | 26,923 | — | $0 | 226,574 | SEC↗ |
| REPH Recro Pharma, Inc. | A Award deriv | 2021-04-13 | 2021-04-15 | 20,000 | — | $0 | 20,000 | SEC↗ |
| BXRX Baudax Bio, Inc. | A Award | 2021-01-20 | 2021-01-22 | 65,435 | — | $0 | 350,307 | SEC↗ |
| REPH Recro Pharma, Inc. | M Exercise deriv | 2021-01-18 | 2021-01-20 | 5,000 | — | $0 | 0 | SEC↗ |
| REPH Recro Pharma, Inc. | F Tax w/h | 2021-01-18 | 2021-01-20 | 6,816 | $3.03 | $20.7K | 199,651 | SEC↗ |
| REPH Recro Pharma, Inc. | M Exercise | 2021-01-18 | 2021-01-20 | 5,000 | — | $0 | 206,467 | SEC↗ |
| REPH Recro Pharma, Inc. | F Tax w/h | 2021-01-02 | 2021-01-05 | 5,599 | $3.09 | $17.3K | 201,467 | SEC↗ |
| REPH Recro Pharma, Inc. | F Tax w/h | 2020-12-05 | 2020-12-09 | 34,128 | $2.30 | $78.5K | 207,066 | SEC↗ |
| BXRX Baudax Bio, Inc. | F Tax w/h | 2020-12-05 | 2020-12-09 | 71,283 | $1.14 | $81.3K | 284,872 | SEC↗ |
| BXRX Baudax Bio, Inc. | F Tax w/h | 2020-12-05 | 2020-12-09 | 11,732 | $1.14 | $13.4K | 356,155 | SEC↗ |
| REPH Recro Pharma, Inc. | M Exercise deriv | 2020-04-17 | 2020-04-20 | 80,000 | — | $0 | 0 | SEC↗ |
| REPH Recro Pharma, Inc. | S Sale | 2020-04-17 | 2020-04-20 | 80,000 | $8.22 | $657.6K | 161,194 | SEC↗ |
| REPH Recro Pharma, Inc. | M Exercise | 2020-04-17 | 2020-04-20 | 80,000 | $2.47 | $197.6K | 321,194 | SEC↗ |
| REPH Recro Pharma, Inc. | S Sale | 2020-04-17 | 2020-04-20 | 80,000 | $8.22 | $657.6K | 241,194 | SEC↗ |
| BXRX Baudax Bio, Inc. | F Tax w/h | 2020-01-27 | 2020-01-29 | 5,051 | $8.51 | $43.0K | 367,887 | SEC↗ |
| BXRX Baudax Bio, Inc. | M Exercise | 2020-01-27 | 2020-01-29 | 19,070 | — | $0 | 372,938 | SEC↗ |
| REPH Recro Pharma, Inc. | M Exercise deriv | 2020-01-18 | 2020-01-22 | 5,000 | — | $0 | 5,000 | SEC↗ |
| REPH Recro Pharma, Inc. | M Exercise | 2020-01-18 | 2020-01-22 | 5,000 | — | $0 | 246,746 | SEC↗ |
| REPH Recro Pharma, Inc. | F Tax w/h | 2020-01-18 | 2020-01-22 | 5,552 | $16.38 | $90.9K | 241,194 | SEC↗ |
| REPH Recro Pharma, Inc. | F Tax w/h | 2020-01-02 | 2020-01-03 | 4,945 | $17.53 | $86.7K | 241,746 | SEC↗ |
| BXRX Baudax Bio, Inc. | A Award deriv | 2019-12-05 | 2019-12-09 | 183,673 | — | $0 | 183,673 | SEC↗ |
| BXRX Baudax Bio, Inc. | A Award | 2019-12-05 | 2019-12-09 | 195,387 | — | $0 | 225,297 | SEC↗ |
| BXRX Baudax Bio, Inc. | A Award | 2019-12-05 | 2019-12-09 | 128,571 | — | $0 | 353,868 | SEC↗ |
| REPH Recro Pharma, Inc. | A Award | 2019-12-05 | 2019-12-09 | 93,550 | — | $0 | 246,691 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | A Award deriv | 2019-06-10 | 2019-06-11 | 16,500 | — | $0 | 16,500 | SEC↗ |
| REPH Recro Pharma, Inc. | M Exercise deriv | 2019-05-13 | 2019-05-15 | 123,500 | — | $0 | 0 | SEC↗ |
| REPH Recro Pharma, Inc. | S Sale | 2019-05-13 | 2019-05-15 | 21,306 | $8.89 | $189.4K | 198,141 | SEC↗ |
| REPH Recro Pharma, Inc. | S Sale | 2019-05-13 | 2019-05-15 | 123,500 | $8.89 | $1.10M | 219,447 | SEC↗ |
| REPH Recro Pharma, Inc. | M Exercise | 2019-05-13 | 2019-05-15 | 123,500 | $2.47 | $305.0K | 342,947 | SEC↗ |
| REPH Recro Pharma, Inc. | A Award deriv | 2019-01-18 | 2019-01-23 | 171,184 | — | $0 | 171,184 | SEC↗ |
| REPH Recro Pharma, Inc. | M Exercise deriv | 2019-01-18 | 2019-01-23 | 5,000 | — | $0 | 10,000 | SEC↗ |
| REPH Recro Pharma, Inc. | M Exercise deriv | 2019-01-18 | 2019-02-19 | 5,000 | — | $0 | 10,000 | SEC↗ |
| REPH Recro Pharma, Inc. | A Award deriv | 2019-01-18 | 2019-02-19 | 190,700 | — | $0 | 190,700 | SEC↗ |
| REPH Recro Pharma, Inc. | F Tax w/h | 2019-01-18 | 2019-01-23 | 1,425 | $7.99 | $11.4K | 214,384 | SEC↗ |
| REPH Recro Pharma, Inc. | A Award | 2019-01-18 | 2019-01-23 | 35,801 | — | $0 | 210,809 | SEC↗ |
| REPH Recro Pharma, Inc. | M Exercise | 2019-01-18 | 2019-01-23 | 5,000 | — | $0 | 215,809 | SEC↗ |
| REPH Recro Pharma, Inc. | M Exercise | 2019-01-18 | 2019-02-19 | 5,000 | — | $0 | 220,872 | SEC↗ |
| REPH Recro Pharma, Inc. | F Tax w/h | 2019-01-18 | 2019-02-19 | 1,425 | $7.99 | $11.4K | 219,447 | SEC↗ |
| REPH Recro Pharma, Inc. | A Award | 2019-01-18 | 2019-02-19 | 40,864 | — | $0 | 215,872 | SEC↗ |
| REPH Recro Pharma, Inc. | F Tax w/h | 2019-01-02 | 2019-01-04 | 4,223 | $7.41 | $31.3K | 175,008 | SEC↗ |
| REPH Recro Pharma, Inc. | F Tax w/h | 2019-01-02 | 2019-01-04 | 4,223 | $7.41 | $31.3K | 175,008 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | A Award deriv | 2018-05-30 | 2018-06-01 | 12,500 | — | $0 | 12,500 | SEC↗ |
| REPH Recro Pharma, Inc. | M Exercise deriv | 2018-01-18 | 2018-01-22 | 5,000 | — | $0 | 15,000 | SEC↗ |
| REPH Recro Pharma, Inc. | M Exercise | 2018-01-18 | 2018-01-22 | 5,000 | — | $0 | 180,806 | SEC↗ |
| REPH Recro Pharma, Inc. | F Tax w/h | 2018-01-18 | 2018-01-22 | 1,575 | $8.89 | $14.0K | 179,231 | SEC↗ |
| REPH Recro Pharma, Inc. | A Award deriv | 2018-01-02 | 2018-01-04 | 100,000 | — | $0 | 100,000 | SEC↗ |
| REPH Recro Pharma, Inc. | A Award | 2018-01-02 | 2018-01-04 | 50,000 | — | $0 | 175,806 | SEC↗ |
| REPH Recro Pharma, Inc. | F Tax w/h | 2017-09-28 | 2017-10-02 | 9,794 | $9.04 | $88.5K | 125,806 | SEC↗ |
| REPH Recro Pharma, Inc. | M Exercise | 2017-09-28 | 2017-10-02 | 31,100 | — | $0 | 135,600 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | A Award deriv | 2017-05-31 | 2017-06-01 | 12,500 | — | $0 | 12,500 | SEC↗ |
| REPH Recro Pharma, Inc. | A Award deriv | 2017-01-18 | 2017-01-20 | 20,000 | — | $0 | 20,000 | SEC↗ |
| REPH Recro Pharma, Inc. | A Award deriv | 2017-01-18 | 2017-01-20 | 144,700 | — | $0 | 144,700 | SEC↗ |
| REPH Recro Pharma, Inc. | A Award deriv | 2016-12-01 | 2016-12-05 | 52,650 | — | $0 | 105,300 | SEC↗ |
| REPH Recro Pharma, Inc. | A Award deriv | 2016-08-01 | 2016-11-03 | 52,650 | — | $0 | 52,650 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | A Award deriv | 2016-06-08 | 2016-06-10 | 10,000 | — | $0 | 10,000 | SEC↗ |
| REPH Recro Pharma, Inc. | A Award deriv | 2015-12-16 | 2015-12-18 | 105,300 | — | $0 | 105,300 | SEC↗ |
| REPH Recro Pharma, Inc. | A Award deriv | 2015-07-25 | 2015-07-28 | 123,500 | — | $0 | 123,500 | SEC↗ |
| REPH Recro Pharma, Inc. | P Buy | 2015-06-08 | 2015-06-09 | 550 | $9.56 | $5.3K | 104,500 | SEC↗ |
| REPH Recro Pharma, Inc. | P Buy | 2015-06-05 | 2015-06-09 | 3,950 | $8.83 | $34.9K | 103,950 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | A Award deriv | 2015-04-15 | 2015-04-16 | 20,000 | — | $0 | 20,000 | SEC↗ |
| REPH Recro Pharma, Inc. | A Award deriv | 2014-12-17 | 2015-07-28 | 123,500 | — | $0 | 123,500 | SEC↗ |
| REPH Recro Pharma, Inc. | A Award deriv | 2014-12-17 | 2015-06-26 | 123,500 | — | $0 | 123,500 | SEC↗ |
| REPH Recro Pharma, Inc. | A Award deriv | 2014-12-17 | 2015-06-26 | 123,500 | — | $0 | 123,500 | SEC↗ |
| REPH Recro Pharma, Inc. | A Award deriv | 2014-12-17 | 2014-12-19 | 123,500 | — | $0 | 123,500 | SEC↗ |
| REPH Recro Pharma, Inc. | A Award deriv | 2014-12-17 | 2014-12-19 | 123,500 | — | $0 | 123,500 | SEC↗ |
| ALKS Alkermes plc. | A Award deriv | 2014-05-28 | 2014-05-30 | 25,000 | — | $0 | 25,000 | SEC↗ |
| REPH Recro Pharma, Inc. | A Award deriv | 2014-04-08 | 2014-04-09 | 40,000 | — | $0 | 40,000 | SEC↗ |
| REPH Recro Pharma, Inc. | A Award deriv | 2014-03-12 | 2014-03-13 | 60,000 | — | $0 | 60,000 | SEC↗ |
| ALKS Alkermes plc. | M Exercise deriv | 2014-01-15 | 2014-01-17 | 20,000 | — | $0 | 0 | SEC↗ |
| ALKS Alkermes plc. | M Exercise deriv | 2014-01-15 | 2014-01-17 | 20,000 | — | $0 | 0 | SEC↗ |
| ALKS Alkermes plc. | M Exercise | 2014-01-15 | 2014-01-17 | 20,000 | $14.04 | $280.8K | 40,000 | SEC↗ |
| ALKS Alkermes plc. | M Exercise | 2014-01-15 | 2014-01-17 | 20,000 | $16.77 | $335.4K | 20,000 | SEC↗ |
| ALKS Alkermes plc. | S Sale | 2014-01-15 | 2014-01-17 | 37,600 | $47.52 | $1.79M | 2,400 | SEC↗ |
| ALKS Alkermes plc. | S Sale | 2014-01-15 | 2014-01-17 | 2,400 | $48.28 | $115.9K | 0 | SEC↗ |
| ALKS Alkermes plc. | M Exercise deriv | 2013-08-29 | 2013-08-30 | 20,000 | — | $0 | 0 | SEC↗ |
| ALKS Alkermes plc. | M Exercise | 2013-08-29 | 2013-08-30 | 20,000 | $13.44 | $268.8K | 20,000 | SEC↗ |
| ALKS Alkermes plc. | S Sale | 2013-08-29 | 2013-08-30 | 20,000 | $31.68 | $633.6K | 0 | SEC↗ |
| ALKS Alkermes plc. | A Award deriv | 2013-08-01 | 2013-08-05 | 25,000 | — | $0 | 25,000 | SEC↗ |
| MAPP MAP Pharmaceuticals, Inc. | D To issuer deriv | 2013-03-01 | 2013-03-04 | 7,500 | — | $0 | 0 | SEC↗ |
| MAPP MAP Pharmaceuticals, Inc. | D To issuer deriv | 2013-03-01 | 2013-03-04 | 5,000 | — | $0 | 0 | SEC↗ |
| MAPP MAP Pharmaceuticals, Inc. | D To issuer deriv | 2013-03-01 | 2013-03-04 | 7,500 | — | $0 | 0 | SEC↗ |
| MAPP MAP Pharmaceuticals, Inc. | M Exercise deriv | 2013-02-28 | 2013-03-04 | 2,500 | — | $0 | 5,000 | SEC↗ |
| MAPP MAP Pharmaceuticals, Inc. | M Exercise deriv | 2013-02-28 | 2013-03-04 | 7,500 | — | $0 | 0 | SEC↗ |
| MAPP MAP Pharmaceuticals, Inc. | M Exercise | 2013-02-28 | 2013-03-04 | 2,500 | $11.69 | $29.2K | 2,500 | SEC↗ |
| MAPP MAP Pharmaceuticals, Inc. | S Sale | 2013-02-28 | 2013-03-04 | 10,000 | $25.00 | $250.0K | 0 | SEC↗ |
| MAPP MAP Pharmaceuticals, Inc. | M Exercise | 2013-02-28 | 2013-03-04 | 7,500 | $12.19 | $91.4K | 10,000 | SEC↗ |
| MAPP MAP Pharmaceuticals, Inc. | M Exercise deriv | 2012-11-23 | 2012-11-27 | 3,750 | — | $0 | 0 | SEC↗ |
| MAPP MAP Pharmaceuticals, Inc. | M Exercise deriv | 2012-11-23 | 2012-11-27 | 1,490 | — | $0 | 0 | SEC↗ |
| MAPP MAP Pharmaceuticals, Inc. | M Exercise | 2012-11-23 | 2012-11-27 | 1,490 | $0.74 | $1.1K | 1,490 | SEC↗ |
| MAPP MAP Pharmaceuticals, Inc. | S Sale | 2012-11-23 | 2012-11-27 | 3,750 | $15.00 | $56.3K | 0 | SEC↗ |
| MAPP MAP Pharmaceuticals, Inc. | M Exercise | 2012-11-23 | 2012-11-27 | 3,750 | $3.18 | $11.9K | 3,750 | SEC↗ |
| MAPP MAP Pharmaceuticals, Inc. | S Sale | 2012-11-23 | 2012-11-27 | 1,490 | $15.00 | $22.4K | 0 | SEC↗ |
| ALKS Alkermes plc. | M Exercise deriv | 2012-08-27 | 2012-08-28 | 20,000 | — | $0 | 0 | SEC↗ |
| ALKS Alkermes plc. | M Exercise | 2012-08-27 | 2012-08-28 | 20,000 | $11.44 | $228.8K | 20,000 | SEC↗ |
| ALKS Alkermes plc. | S Sale | 2012-08-27 | 2012-08-28 | 20,000 | $17.80 | $356.0K | 0 | SEC↗ |
| ALKS Alkermes plc. | M Exercise deriv | 2012-08-24 | 2012-08-28 | 20,000 | — | $0 | 0 | SEC↗ |
| ALKS Alkermes plc. | M Exercise | 2012-08-24 | 2012-08-28 | 20,000 | $11.84 | $236.8K | 20,000 | SEC↗ |
| ALKS Alkermes plc. | S Sale | 2012-08-24 | 2012-08-28 | 20,000 | $17.94 | $358.8K | 0 | SEC↗ |
| ALKS Alkermes plc. | A Award deriv | 2012-08-01 | 2012-08-02 | 25,000 | — | $0 | 25,000 | SEC↗ |
| MAPP MAP Pharmaceuticals, Inc. | A Award deriv | 2012-05-17 | 2012-05-21 | 10,000 | — | $0 | 10,000 | SEC↗ |
| ALKS Alkermes plc. | M Exercise deriv | 2012-02-23 | 2012-02-23 | 1,600 | — | $0 | 0 | SEC↗ |
| ALKS Alkermes plc. | M Exercise | 2012-02-23 | 2012-02-23 | 1,600 | $8.98 | $14.4K | 1,600 | SEC↗ |
| ALKS Alkermes plc. | S Sale | 2012-02-23 | 2012-02-23 | 1,600 | $17.31 | $27.7K | 0 | SEC↗ |
| ALKS Alkermes plc. | M Exercise deriv | 2012-02-22 | 2012-02-23 | 18,400 | — | $0 | 1,600 | SEC↗ |
| ALKS Alkermes plc. | M Exercise deriv | 2012-02-22 | 2012-02-23 | 20,000 | — | $0 | 0 | SEC↗ |
| ALKS Alkermes plc. | M Exercise deriv | 2012-02-22 | 2012-02-23 | 8,000 | — | $0 | 0 | SEC↗ |
| ALKS Alkermes plc. | S Sale | 2012-02-22 | 2012-02-23 | 18,400 | $17.29 | $318.1K | 0 | SEC↗ |
| ALKS Alkermes plc. | M Exercise | 2012-02-22 | 2012-02-23 | 18,400 | $8.98 | $165.2K | 18,400 | SEC↗ |
| ALKS Alkermes plc. | S Sale | 2012-02-22 | 2012-02-23 | 8,000 | $17.29 | $138.3K | 0 | SEC↗ |
| ALKS Alkermes plc. | M Exercise | 2012-02-22 | 2012-02-23 | 8,000 | $9.91 | $79.3K | 8,000 | SEC↗ |
| ALKS Alkermes plc. | M Exercise | 2012-02-22 | 2012-02-23 | 20,000 | $9.91 | $198.2K | 20,000 | SEC↗ |
| ALKS Alkermes plc. | S Sale | 2012-02-22 | 2012-02-23 | 20,000 | $17.29 | $345.8K | 0 | SEC↗ |